entertainment -WSS

entertainment

author：explore 2025-10-01 05:39:49 - browse：447

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

Eli Lilly’s blockbuster diabetes and obesity drug improved living scarring in a mid-stage study of the liver disease MASH, adding to positive data announced earlier this year.

The study tested three doses of tirzepatide, sold commercially as Mounjaro or Zepbound. The percentage of patients who experienced a greater than one-stage improvement in scarring, or fibrosis, without worsening of their disease was 54.9%, 51.3%, and 51.0% from the lowest to highest doses.

When compared with the 29.7% of patients on placebo who achieved this outcome, the results were statistically significant, according to an abstract of data that will be presented at the annual meeting of the European Association for the Study of the Liver.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： High breast density mammograms need follow

WSS

Liz Cheney makes 1st public comment since Trump's election interference indictments

ProMED sees offers of support, but its future remains unclear

Mass General, Mayo Clinic look to monetize custom

An interview with Robert F. Kennedy Jr. on vaccines

Baltimore teen accused of firing into crowd during block party mass shooting

Beware the threat of staffing cuts at the CDC

explore

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Medical leaders decry Supreme Court decision on affirmative action

Trump's false claims about Georgia's 2020 election long debunked

Apple is now the first public company to be valued at $3 trillion

Living with Hashimoto's and celiac disease, and med school, too

Jerome Adams on the need for new antivirals for Covid

Head of FDA's diagnostics center, who led through Covid, retires

Cancer drug shortages should be causing more outrage

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Psychedelics group wrestles with new pharma identity

Update the Apgar Score to remove skin color

focus

FDA sets aggressive timeline for overhauling inspection procedures

Patient advocates sound warning on FDA proposal on salt intake

What causes osteoarthritis? Researchers study link to brain protein

As Maui death toll rises, number of missing remains unclear

Microsoft launches AI tool for clinical documentation through Epic

Hilary may become 1st tropical storm to make landfall in California in 84 years

focus

explore

focus

focus